p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients

[1]  J. Hickman,et al.  Apoptosis induced by anticancer drugs , 1992, Cancer and Metastasis Reviews.

[2]  D M Barnes,et al.  Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay. , 2000, The Journal of molecular diagnostics : JMD.

[3]  H. Saya,et al.  Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx , 2000, International journal of cancer.

[4]  M. Gnant,et al.  TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  P. Chappuis,et al.  Prognostic significance of p53 mutation in breast cancer: Frequent detection of non‐missense mutations by yeast functional assay , 1999, International journal of cancer.

[6]  Ruggero Montesano,et al.  IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines , 1999, Human mutation.

[7]  W. Reinhold,et al.  Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  R. Iggo,et al.  High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay , 1997, Oncogene.

[9]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[10]  Jun O. Liu,et al.  p53-independent apoptosis induced by paclitaxel through an indirect mechanism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Dowsett,et al.  Preoperative chemotherapy induces apoptosis in early breast cancer , 1997, The Lancet.

[12]  R. Iggo,et al.  Field cancerisation and polyclonal p53 mutation in the upper aero- digestive tract , 1997, Oncogene.

[13]  A. Hartmann,et al.  The molecular epidemiology of p53 gene mutations in human breast cancer. , 1997, Trends in genetics : TIG.

[14]  J. Brown,et al.  Cell status — dead or alive? , 1996, Nature Medicine.

[15]  H. Abe,et al.  Clonality and stability of the p53 gene in human astrocytic tumor cells: Quantitative analysis of p53 gene mutations by yeast functional assay , 1996, International journal of cancer.

[16]  H. Nguyen,et al.  Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. , 1996, Carcinogenesis.

[17]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[18]  L. Holmberg,et al.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. , 1996, Journal of the National Cancer Institute.

[19]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[20]  J C Reed,et al.  Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.

[21]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.

[22]  E. Lazarides,et al.  Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway , 1995, Molecular medicine.

[23]  P. Chappuis,et al.  A simple p53 functional assay for screening cell lines, blood, and tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[25]  R. Iggo,et al.  A rapid PCR fidelity assay. , 1994, Nucleic acids research.

[26]  B. Vojtesek,et al.  Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. , 1994, British Journal of Cancer.

[27]  Stephen L. George,et al.  Sample size requirements and length of study for testing interaction in a 1 × k factorial design when time-to-failure is the outcome , 1993 .

[28]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[29]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.